Cargando…

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort

OBJECTIVE: Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts, osteoporosis and avascular necrosis that is attributable to cumulative corticosteroid exposure in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Julie E, Fu, Qinggong, Rao, Sapna, Magder, Laurence S, Petri, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950698/ https://www.ncbi.nlm.nih.gov/pubmed/29765616 http://dx.doi.org/10.1136/lupus-2017-000237

Ejemplares similares

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?
por: Magder, Laurence S, et al.
Publicado: (2023)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
por: Nived, Ola, et al.
Publicado: (2020)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2022)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2021)

Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2017)

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres
por: Tani, Chiara, et al.
Publicado: (2018)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d5sepfkr2rvk2184ve5v9linpb